Breast Cancer Drug List in China: Common Endocrine, Targeted, ADC, and Chemotherapy Drugs

The breast cancer drug list in China mainly includes endocrine therapy drugs, HER2-targeted drugs, CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, antibody-drug conjugates (ADCs), chemotherapy drugs, and immunotherapy drugs.

Breast cancer is one of the most common malignant tumors. Treatment options vary depending on hormone receptor (HR) status, HER2 status, BRCA mutations and other genetic alterations, disease stage, and previous treatments.

DengYueMed, a China-based pharmaceutical wholesaler, has organized representative breast cancer drugs approved in China by drug category to help patients, healthcare professionals, pharmaceutical buyers, and other readers quickly understand the major treatment options available in the Chinese market.

Quick Facts: Breast Cancer Drug List in China

The breast cancer drug list in China covers the following major treatment categories:

Drug Category	Representative Drugs	Main Applications
Endocrine Therapy	Tamoxifen, Letrozole, Fulvestrant, Elacestrant	HR-positive breast cancer
HER2-Targeted Drugs	Trastuzumab, Pertuzumab, Pyrotinib, Tucatinib	HER2-positive breast cancer
CDK4/6 Inhibitors	Palbociclib, Ribociclib, Abemaciclib, Dalpiciclib	HR+/HER2- breast cancer
mTOR Inhibitors	Everolimus	Advanced HR+/HER2- breast cancer
HDAC Inhibitors	Entinostat	Locally advanced or metastatic HR+/HER2- breast cancer
PARP Inhibitors	Olaparib, Fluzoparib	Breast cancer with specific BRCA mutations
ADCs	Ado-trastuzumab emtansine, Trastuzumab deruxtecan, Trastuzumab rezetecan, etc.	HER2-positive, HER2-low, TNBC, and selected HR+/HER2- breast cancers
Chemotherapy	Paclitaxel, Docetaxel, Doxorubicin, Eribulin, etc.	Multiple breast cancer settings
Immunotherapy	Pembrolizumab, Toripalimab, Atezolizumab	Selected TNBC

Note: Breast cancer drugs and approved indications continue to evolve. Some drugs, generics, biosimilars, or newly approved indications may not be included in this list. If you would like information about a specific breast cancer drug not listed here, its availability, or breast cancer medicines in the Chinese market, you can further consult DengYueMed.

1. Endocrine Therapy Drugs for Breast Cancer

Endocrine therapy is mainly used for hormone receptor-positive (HR+) breast cancer. It includes selective estrogen receptor modulators, aromatase inhibitors, estrogen receptor degraders, and ovarian function suppression therapies.

Drug Name	Drug Class	Main Breast Cancer Application
Tamoxifen	SERM	HR-positive breast cancer
Toremifene	SERM	HR-positive breast cancer
Letrozole	Aromatase inhibitor	HR-positive breast cancer
Anastrozole	Aromatase inhibitor	HR-positive breast cancer
Exemestane	Aromatase inhibitor	HR-positive breast cancer
Fulvestrant	SERD	Advanced or metastatic HR-positive breast cancer
Elacestrant	Oral SERD	ESR1-mutated, HR+/HER2- advanced or metastatic breast cancer
Goserelin	GnRH agonist	Selected premenopausal patients with HR-positive breast cancer
Leuprorelin	GnRH agonist	Selected premenopausal patients with HR-positive breast cancer

These endocrine therapies form an important part of breast cancer treatment drugs in China, particularly for patients with HR-positive disease.

2. HER2-Targeted Drugs for Breast Cancer

HER2-positive breast cancer can be treated with HER2-targeted monoclonal antibodies or small-molecule tyrosine kinase inhibitors (TKIs), depending on disease stage and previous treatment.

Inetetamab and Pyrotinib are representative HER2-targeted drugs developed by Chinese pharmaceutical companies and provide additional treatment options for HER2-positive breast cancer.

Drug Name	Drug Class	Main Breast Cancer Application
Trastuzumab	HER2 monoclonal antibody	Early and advanced HER2-positive breast cancer
Pertuzumab	HER2 monoclonal antibody	Early and advanced HER2-positive breast cancer
Inetetamab	HER2 monoclonal antibody	Metastatic HER2-positive breast cancer
Pyrotinib	HER family TKI	Advanced or metastatic HER2-positive breast cancer
Lapatinib	HER1/HER2 TKI	Advanced HER2-positive breast cancer
Neratinib	HER family TKI	Extended adjuvant therapy for early HER2-positive breast cancer
Tucatinib	HER2 TKI	Locally advanced or metastatic HER2-positive breast cancer

It is important to note that ADCs can also target HER2. Therefore, HER2-targeted drugs and ADCs are not completely separate categories, and some overlap between the two sections is expected.

3. CDK4/6, mTOR, HDAC, and PARP Inhibitors

These targeted therapies are mainly used for patients with specific molecular characteristics and play an important role in the treatment of HR+/HER2- breast cancer.

Drug Name	Drug Class	Main Breast Cancer Application
Palbociclib	CDK4/6 inhibitor	Locally advanced or metastatic HR+/HER2- breast cancer
Ribociclib	CDK4/6 inhibitor	Advanced and selected early HR+/HER2- breast cancer
Abemaciclib	CDK4/6 inhibitor	Advanced and selected high-risk early HR+/HER2- breast cancer
Dalpiciclib	CDK4/6 inhibitor	Advanced HR+/HER2- breast cancer
Culmerciclib	CDK2/4/6 inhibitor	Locally advanced or metastatic HR+/HER2- breast cancer
Everolimus	mTOR inhibitor	Advanced HR+/HER2- breast cancer
Entinostat	HDAC inhibitor	Locally advanced or metastatic HR+/HER2- breast cancer, combined with an aromatase inhibitor after endocrine therapy
Olaparib	PARP inhibitor	HER2-negative breast cancer with specific BRCA mutations
Fluzoparib	PARP inhibitor	Advanced HER2-negative breast cancer with specific BRCA mutations

Dalpiciclib, Culmerciclib, and Fluzoparib are representative breast cancer targeted therapies developed by Chinese pharmaceutical companies.

These drugs are also important examples when reviewing a breast cancer drug list in China, particularly for precision treatment based on molecular and biomarker characteristics.

4. Breast Cancer ADC Drugs

Antibody-drug conjugates (ADCs) combine a targeted antibody with a cytotoxic payload. By recognizing specific targets on tumor cells, ADCs can deliver the cytotoxic drug more selectively to cancer cells.

Representative breast cancer ADC drugs available in China include HER2-targeted ADCs and TROP-2-targeted ADCs.

Drug Name	Drug Class	Main Target	Main Breast Cancer Application
Ado-trastuzumab emtansine	ADC	HER2	HER2-positive breast cancer
Trastuzumab deruxtecan	ADC	HER2	HER2-positive and selected HER2-low/ultralow breast cancer
Disitamab vedotin	ADC	HER2	Selected HER2-positive breast cancer
Sacituzumab govitecan	ADC	TROP-2	Selected TNBC and advanced HR+/HER2- breast cancer
Trastuzumab rezetecan	ADC	HER2	HER2-positive locally advanced or metastatic breast cancer after previous anti-HER2 treatment
Trastuzumab botidotin	ADC	HER2	HER2-positive unresectable or metastatic breast cancer after previous anti-HER2 treatment
Sacituzumab tirumotecan	ADC	TROP-2	TNBC and selected advanced or metastatic HR+/HER2- breast cancer
Datopotamab deruxtecan	ADC	TROP-2	Unresectable or metastatic HR+/HER2- breast cancer after endocrine therapy and at least one line of chemotherapy

Disitamab vedotin, Trastuzumab rezetecan, and Sacituzumab tirumotecan are representative examples of the development of breast cancer ADCs by Chinese pharmaceutical companies.

The rapid development of HER2 and TROP-2 ADCs has become an important part of the evolving breast cancer drug list in China.

5. Breast Cancer Chemotherapy Drugs

Chemotherapy remains an important component of breast cancer treatment and may be used in selected patients for neoadjuvant therapy, adjuvant therapy, and advanced or metastatic breast cancer.

Drug Name	Drug Class	Main Breast Cancer Application
Doxorubicin	Anthracycline	Early and advanced breast cancer
Epirubicin	Anthracycline	Early and advanced breast cancer
Paclitaxel	Taxane	Neoadjuvant, adjuvant, and advanced breast cancer
Docetaxel	Taxane	Neoadjuvant, adjuvant, and advanced breast cancer
Albumin-bound paclitaxel	Taxane	Multiple breast cancer treatment settings
Cyclophosphamide	Alkylating agent	Multiple combination chemotherapy regimens
Carboplatin	Platinum agent	Selected TNBC and other treatment settings
Cisplatin	Platinum agent	Selected TNBC and other treatment settings
Capecitabine	Fluoropyrimidine	Advanced or metastatic breast cancer
Gemcitabine	Antimetabolite	Advanced or metastatic breast cancer
Vinorelbine	Vinca alkaloid	Advanced or metastatic breast cancer
Eribulin	Microtubule inhibitor	Advanced or metastatic breast cancer
Utidelone	Microtubule inhibitor	Recurrent or metastatic breast cancer

These commonly used breast cancer chemotherapy drugs remain an important part of systemic treatment, particularly when chemotherapy is indicated based on tumor subtype, disease stage, and previous treatment.

6. Breast Cancer Immunotherapy Drugs

Immune checkpoint inhibitors are mainly used for selected patients with triple-negative breast cancer (TNBC). Whether immunotherapy is appropriate depends on biomarkers such as PD-L1 status, as well as disease stage and previous treatment.

Drug Name	Drug Class	Main Breast Cancer Application
Pembrolizumab	PD-1 inhibitor	Selected early, locally advanced, or metastatic TNBC
Toripalimab	PD-1 inhibitor	PD-L1-positive recurrent or metastatic TNBC
Atezolizumab	PD-L1 inhibitor	PD-L1-positive unresectable locally advanced or metastatic TNBC

Common Drugs by Breast Cancer Type

The following summary provides a simplified overview of breast cancer drugs in China according to major breast cancer subtypes, with reference to clinical recommendations from the Chinese Society of Clinical Oncology (CSCO).

Breast Cancer Type	Main Drug Categories	Representative Drugs
HR+/HER2- breast cancer	Endocrine therapy, CDK4/6 inhibitors, mTOR inhibitors, selected ADCs	Letrozole, Fulvestrant, Abemaciclib, Everolimus
HER2-positive breast cancer	HER2-targeted therapy, ADCs, chemotherapy	Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine, Trastuzumab deruxtecan
Triple-negative breast cancer	Chemotherapy, immunotherapy, ADCs	Paclitaxel, Pembrolizumab, Toripalimab, Sacituzumab govitecan
BRCA-mutated, HER2-negative breast cancer	PARP inhibitors	Olaparib, Fluzoparib
ESR1-mutated, HR+/HER2- breast cancer	Endocrine therapy	Elacestrant

Conclusion

China offers a broad range of breast cancer treatments, including endocrine therapies, targeted drugs, ADCs, chemotherapy, and immunotherapy. As pharmaceutical innovation advances, the breast cancer drug list in China continues to expand.

For overseas hospitals, distributors, and pharmaceutical buyers, China provides access to innovative medicines, generics, biosimilars, and established therapies.

DengYueMed is a Hong Kong-based pharmaceutical wholesaler specializing in pharmaceutical procurement and international supply, with a focus on oncology, rare diseases, hematology, autoimmune diseases, and other specialty medicines.

FAQ about Breast Cancer Drug List in China